Constantine Si Lun Tam, Brad S. Kahl, Talha Munir, Tadeusz Robak, Paolo Ghia, Stephen Opat, Patricia Walker, Masa Lasica, Ian W. Flinn, Wojciech Jurczak, Jiayi Shen, Marcus Lefebure, Jamie H. Hirata, Mazyar Shadman. "Subsequent therapies and time to second progression-free survival events (PFS2) in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL) previously treated with zanubrutinib (zanu) or bendamustine-rituximab (BR) in SEQUOIA.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.7046